Carregant...
Rapid emergence of protease inhibitor resistance in hepatitis C virus
Approximately 170 million people worldwide are infected with hepatitis C virus (HCV). Current standard therapy leads to sustained viral elimination in only about 50% of patients treated. Telaprevir, a novel HCV protease inhibitor, has demonstrated substantial antiviral activity in patients with chro...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3033690/ https://ncbi.nlm.nih.gov/pubmed/20445200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3000544 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|